

THIS CIRCULAR TO SHAREHOLDERS OF CENGILD MEDICAL BERHAD (“CENGILD MEDICAL” OR “COMPANY”) IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION.

If you are in any doubt as to the course of action to be taken, you should consult your stockbroker, bank manager, solicitor, accountant or other professional adviser immediately.

Bursa Malaysia Securities Berhad (“**Bursa Securities**”) takes no responsibility for the contents of this Circular, makes no representation as to its accuracy or completeness and expressly disclaims any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this Circular.



CENGILD MEDICAL BERHAD

Registration No.: 202101004143 (1404442-P)
(Incorporated in Malaysia)

CIRCULAR TO SHAREHOLDERS

IN RELATION TO THE

PROPOSED VARIATION AND EXTENSION OF TIMEFRAME FOR THE UTILISATION OF PROCEEDS RAISED FROM THE INITIAL PUBLIC OFFERING OF CENGILD MEDICAL PURSUANT TO RULE 8.24 OF THE ACE MARKET LISTING REQUIREMENTS OF BURSA SECURITIES (“PROPOSED VARIATION”)

AND

NOTICE OF EXTRAORDINARY GENERAL MEETING

The Proposed Variation will be tabled at our Extraordinary General Meeting (“**EGM**”), which will be held at Nexus, Connexion Conference & Event Centre, Spectrum (Level 3A), Bangsar South City, No. 7, Jalan Kerinchi, 59200 Kuala Lumpur, Malaysia on **Friday, 28 November 2025 at 4:00 p.m.** or any adjournment thereof, or following the conclusion of the 5th Annual General Meeting, whichever is later. The Notice of EGM of our Company together with the Proxy Form are enclosed in this Circular.

You are entitled to attend and vote at the EGM of our Company or to appoint a proxy or proxies to attend and vote on your behalf. The Proxy Form must be lodged at the office of our Share Registrar located at Unit 32-01, Level 32, Tower A, Vertical Business Suite, Avenue 3, Bangsar South, No. 8, Jalan Kerinchi, 59200 Kuala Lumpur or alternatively, at the drop-in box located at Unit G-3, Ground Floor, Vertical Podium, Avenue 3, Bangsar South, No. 8, Jalan Kerinchi, 59200 Kuala Lumpur or by electronic lodgement via the portal at <https://srmy.vistra.com> on or before the time and date indicated below should you be unable to attend the meeting. The lodging of the Proxy Form will not preclude you from attending and voting in person at the meeting if you subsequently wish to do so.

Date and time of our EGM	: Friday, 28 November 2025 at 4:00 p.m.
Last date and time for lodging the Proxy Form	: Wednesday, 26 November 2025 at 4:00 p.m.

This Circular is dated 30 October 2025

DEFINITIONS

Except where the context otherwise requires, the following definitions shall apply throughout this Circular:

Acquisition	: Acquisition by Cengild Sdn Bhd, of the Property for a purchase consideration of RM122,340,668.00
Board	: Board of Directors of Cengild Medical
Bursa Securities	: Bursa Malaysia Securities Berhad
Cengild Medical or Company	: Cengild Medical Berhad
Cengild Medical Group or Group	: Cengild Medical and its subsidiaries, collectively
Circular	: This circular to our shareholders dated 30 October 2025 in relation to the Proposed Variation
Directors	: A natural person who holds a directorship in our Group and shall have the meaning given in Section 2(1) of the Malaysian Companies Act 2016 and Section 2(1) of the Capital Markets and Services Act, 2007
EGM	: Extraordinary general meeting
EPS	: Earnings per Share
FYE	: Financial year ended
IPO	: Initial public offering exercise in conjunction with the listing of Cengild Medical on ACE Market of Bursa Securities on 18 April 2022
IPO Proceeds	: Total gross proceeds of RM72.20 million raised from Cengild Medical's IPO
IPO Prospectus	: The prospectus dated 30 March 2022 issued in conjunction with the IPO
Listing Date	: The listing date on 18 April 2022
Listing Requirements	: ACE Market Listing Requirements of Bursa Securities
LPD	: 30 September 2025, being the latest practicable date prior to the printing of this Circular
Property	: A stratified property with a combined strata floor area of 100,442 sq ft together with at least 182 carpark bays forming part of a purpose-built private medical centre
Proposed Variation	: Proposed variation and extension of timeframe for the utilisation of proceeds raised from the IPO of Cengild Medical pursuant to Rule 8.24 of the Listing Requirements
Share(s)	: Ordinary shares in Cengild Medical

DEFINITIONS (CONT'D)

SPA : Conditional sale and purchase agreement dated 29 December 2023 entered into between Cengild Sdn Bhd and Sunny Uptown Sdn Bhd for the Acquisition. The conditions precedent of the sale and purchase agreement have been fulfilled and become unconditional on 17 October 2024.

Sq ft : Square feet

CURRENCY

RM and sen : Ringgit Malaysia and sen, respectively

References to “we”, “us”, “our” and “ourselves” are to our Company and where the context requires, shall include our subsidiaries. All references to “you” in this Circular are referred to Cengild Medical’s shareholders.

Words incorporating the singular shall, where applicable, include the plural and vice versa. Words incorporating the masculine gender shall, where applicable, include the feminine and neuter genders and vice versa. Any reference to persons shall include a corporation, unless otherwise specified.

Any reference in this Circular to any enactment is a reference to that enactment as for the time being amended or re-enacted. Any reference to a time of a day in this Circular shall be reference to Malaysian time, unless otherwise specified.

[The rest of this page is intentionally left blank]

TABLE OF CONTENTS

	PAGE
EXECUTIVE SUMMARY	iv
LETTER TO OUR SHAREHOLDERS ON THE PROPOSED VARIATION	
1. INTRODUCTION	1
2. DETAILS OF THE PROPOSED VARIATION	1
3. RATIONALE FOR THE PROPOSED VARIATION	4
4. EFFECTS OF THE PROPOSED VARIATION	4
5. APPROVALS REQUIRED AND CONDITIONALITY	4
6. INTER-CONDITIONALITY	4
7. INTEREST OF DIRECTORS, MAJOR SHAREHOLDERS AND/OR PERSONS CONNECTED WITH THEM	4
8. DIRECTORS' STATEMENT	5
9. ESTIMATED TIMEFRAME FOR COMPLETION	5
10. PROPOSALS ANNOUNCED BUT PENDING COMPLETION	5
11. EGM	5
12. FURTHER INFORMATION	5
APPENDIX	
I. FURTHER INFORMATION	6
NOTICE OF EGM	ENCLOSED
PROXY FORM	ENCLOSED

EXECUTIVE SUMMARY

THIS EXECUTIVE SUMMARY HIGHLIGHTS THE SALIENT INFORMATION OF THE PROPOSED VARIATION. YOU ARE ADVISED TO READ AND CONSIDER CAREFULLY THE ENTIRE CONTENTS OF THIS CIRCULAR AND THE APPENDIX AND NOT RELY SOLELY ON THIS EXECUTIVE SUMMARY IN FORMING A DECISION ON THE PROPOSED VARIATION BEFORE VOTING ON THE RESOLUTION PERTAINING TO THE PROPOSED VALUATION TO BE TABLED AT OUR FORTHCOMING EGM.

Summary		Reference in this Circular
Details of the Proposed Variation	<p>: As at LPD, we have utilised RM48.00 million from the total IPO Proceeds and the remaining balance of RM24.20 million has yet to be utilised.</p> <p>After due consideration of the rationale set out in Section 3 of this Circular, our Board proposes to:</p> <ul style="list-style-type: none">(i) vary the balance unutilised IPO Proceeds earmarked for the establishment of new medical centres amounting to RM18.55 million to finance the purchase of medical equipment within 36 months from the unconditional date of the SPA for the Acquisition; and(ii) extend the timeframe for the utilisation of working capital up to 48 months from the Listing Date ("Second Extension"). <p>Please refer to Section 2 of this Circular for further details of the Proposed Variation.</p>	Section 2
Rationale for the Proposed Variation	: The Proposed Variation is intended to finance the purchase of new medical equipment and our Board is of the opinion that it is consistent with our future plans in expanding our operations of core specialities in gastroenterology and hepatology, and our complementary medical services to provide patients with more comprehensive medical care and treatment. The Proposed Variation provides our Group with an opportunity to achieve our future plans and is expected to contribute positively to our Group.	Section 3
Effects of the Proposed Variation	: The Proposed Variation will not have any effect on our issued share capital, substantial shareholders' shareholdings, net assets, gearing and earnings per Share.	Section 4
Approvals required and confidentiality	: The Proposed Variation is subject to the approval from our shareholders at an EGM to be convened.	Section 5
	The Second Extension is not subject to the approval from our shareholders.	
Inter-conditionality	: The Proposed Variation is not conditional upon any other corporate proposal undertaken or to be undertaken by our Company.	Section 6

EXECUTIVE SUMMARY (CONT'D)

Summary		Reference in this Circular
Interest of Directors, major shareholders and/or persons connected with them	: None of our Directors and/or major shareholders and/or persons connected to them has any interest, whether direct or indirect, in the Proposed Variation.	Section 7
Directors' statement	: Our Board, after taking into consideration all aspects of the Proposed Variation and Second Extension, including the rationale and effects of the Proposed Variation, and after careful deliberation, is of the opinion that the Proposed Variation and Second Extension are in the best interest of our Group.	Section 8

[The rest of this page is intentionally left blank]



CENGILD MEDICAL BERHAD

Registration No.: 202101004143 (1404442-P)
(Incorporated in Malaysia)

Registered Office:

Unit 30-01, Level 30
Tower A, Vertical Business Suite
Avenue 3, Bangsar South
No. 8, Jalan Kerinchi
59200 Kuala Lumpur

30 October 2025

Board of Directors:

Dato' Dr. Tan Huck Joo (*Executive Chairman*)
Dr. Mohamed Akhtar Bin Mohamed Ditali Qureshi (*Executive Director*)
Dr. Chong Su-Lin (*Independent Non-Executive Director*)
Dr. Azrina Binti Abu Bakar (*Independent Non-Executive Director*)
Dr. Yap Tat Hiung (*Independent Non-Executive Director*)

To: Our shareholders

Dear Sir / Madam,

PROPOSED VARIATION

1. INTRODUCTION

On 24 September 2025, our Board announced that our Company proposes to undertake the Proposed Variation.

Further details of the Proposed Variation are set out in the ensuing sections of this Circular.

THE PURPOSE OF THIS CIRCULAR IS TO PROVIDE YOU WITH THE RELEVANT INFORMATION ON THE PROPOSED VARIATION AND TO SEEK YOUR APPROVAL FOR THE ORDINARY RESOLUTION PERTAINING TO THE PROPOSED VARIATION TO BE TABLED AT OUR FORTHCOMING EGM. THE NOTICE OF EGM AND THE PROXY FORM ARE ENCLOSED IN THIS CIRCULAR.

YOU ARE ADVISED TO READ AND CONSIDER CAREFULLY THE CONTENTS OF THIS CIRCULAR TOGETHER WITH THE ENSUING APPENDIX BEFORE VOTING ON THE RESOLUTION PERTAINING TO THE PROPOSED VARIATION TO BE TABLED AT OUR FORTHCOMING EGM.

2. DETAILS OF THE PROPOSED VARIATION

Reference is made to the use of proceeds raised from the public issue as disclosed in our Company's IPO Prospectus on Listing Date. We raised a total gross proceeds of RM72.20 million from our IPO.

Since the completion of our IPO, our Company had on 29 December 2023 and 29 March 2024 announced the variation of the utilisation of IPO Proceeds and extension of time for the use of IPO Proceeds (“**First Variation & First Extension**”) to part finance the Acquisition.

The details of the First Variation and First Extension which was set out in the circular dated 26 April 2024 are as follows for ease of reference:

Details of utilisation	(A)	(B)	(C) = (A) - (B)		Revised utilisation after the First Variation	Original timeframe for utilisation of proceeds	Revised timeframe for utilisation after the First Extension
	Proposed utilisation during the IPO	Actual utilisation as at 15 April 2024	Balance of proceeds as at 15 April 2024	First Variation			
	RM'000	RM'000	RM'000	RM'000	RM'000		
Expansion of existing medical centre	13,000	3,092	9,908	(9,908)	-	Within 36 months from the Listing Date	-
Establishing new medical centres	37,100	-	37,100	(18,550)	18,550	Within 36 months from the Listing Date	-
Acquisition	-	-	-	36,258	36,258	-	Within 36 months from the unconditional date of the SPA
Working capital	17,404	4,153	13,251	(7,800)	5,654	Within 24 months from the Listing Date	Within 36 months from the Listing Date*
Defraying the listing expenses	4,700	4,497	203	-	-	Within 1 month from the Listing Date	-
Total	72,204	11,742	60,462	-	60,462		

On 13 May 2024, our Company has obtained shareholders' approval for the Acquisition and First Variation & First Extension.

As at LPD, we have utilised RM48.00 million from the total IPO Proceeds and the remaining balance of RM24.20 million has yet to be utilised.

After due consideration of the rationale set out in **Section 3** of this Circular, our Board proposes to:

- (i) vary the balance unutilised IPO Proceeds earmarked for the establishment of new medical centres amounting to RM18.55 million to finance the purchase of medical equipment within 36 months from the unconditional date of the SPA for the Acquisition; and
- (ii) Second Extension.

The details of the Proposed Variation and extension of time for the use of IPO Proceeds are as follows:

Details of utilisation	Intended use of proceeds after the First Variation	Amount to be varied under the Proposed Variation		Balance to be utilised after the Proposed Variation	Revised timeframe for utilisation after the	
		RM'000	Amount utilised as at the LPD		First Extension	Second Extension
		RM'000	RM'000	RM'000		
	Expansion of existing medical centre	3,092	(3,092)	-	-	-
	Establishing new medical centres ⁽¹⁾	18,550	-	(18,550)	-	-
	Acquisition	36,258	(36,258)	-	Within 36 months from the unconditional date of the SPA	-
	Purchase of new medical equipment ⁽¹⁾	-	-	18,550	-	Within 36 months from the unconditional date of the SPA
	Working capital	9,807	(4,153)	-	Within 36 months from the Listing Date	Within 48 months from the Listing Date
	Defraying the listing expenses	4,497	(4,497)	-	-	-
Total		72,204	(48,000)	-		24,204

Note:

- (1) As summarised in our Company's circular dated 26 April 2024, the revised utilisation earmarked for the establishing new medical centre was approximately RM18.55 million after the First Variation. While our Company still intends to expand its existing medical centre, it will be carried out via the Acquisition as opposed to its earlier plans of leasing additional space of approximately 12,000 to 15,000 sq ft at Nexus @ Bangsar South as disclosed in the IPO Prospectus.

As such, the Proposed Variation of approximately RM18.55 million is intended to be utilised to finance the purchase of new medical equipment which have been identified such as radiological equipment set which include computed tomography (CT) scan, magnetic resonance imaging (MRI), fluoroscopy, digital X-ray and mobile X-ray which is expected to be fully utilised within 36 months from the unconditional date of the SPA, being 17 October 2024. As at the LPD, we have issued purchase order for the new medical equipment and paid a deposit of approximately RM3.18 million from our internally generated funds. The abovementioned new medical equipments are intended to be installed and operate at our new medical centre at Bangsar South, Kuala Lumpur.

The variation of the IPO Proceeds for the amount of approximately RM18.55 million represents 25.69% of the total IPO Proceeds. As such, in accordance with Rule 8.24(2)(a) of the Listing Requirements, the Proposed Variation is deemed a material change to the utilisation of IPO Proceeds. Accordingly, the shareholders' approval for the Proposed Variation is required to be obtained by our Company.

3. RATIONALE FOR THE PROPOSED VARIATION

The Proposed Variation is intended to finance the purchase of new medical equipment and our Board is of the opinion that it is consistent with our future plans in expanding our operations of core specialities in gastroenterology and hepatology, and our complementary medical services to provide patients with more comprehensive medical care and treatment.

After considering various available options, the Proposed Variation provides our Group with an opportunity to achieve our future plans and is expected to contribute positively to our Group.

4. EFFECTS OF THE PROPOSED VARIATION

The Proposed Variation will not have any effect on our issued share capital, substantial shareholders' shareholdings, net assets, gearing and earnings per Share.

5. APPROVALS REQUIRED AND CONDITIONALITY

The Proposed Variation is subject to the approval from our shareholders at an EGM to be convened.

The Second Extension is not subject to the approval from our shareholders.

6. INTER-CONDITIONALITY

The Proposed Variation is not conditional upon any other corporate proposal undertaken or to be undertaken by our Company.

7. INTEREST OF DIRECTORS, MAJOR SHAREHOLDERS AND/OR PERSONS CONNECTED WITH THEM

None of our Directors and/or major shareholders and/or persons connected to them has any interest, whether direct or indirect, in the Proposed Variation.

8. DIRECTORS' STATEMENT

Our Board, after taking into consideration all aspects of the Proposed Variation and Second Extension, including the rationale and effects of the Proposed Variation, and after careful deliberation, is of the opinion that the Proposed Variation and Second Extension are in the best interest of our Group.

9. ESTIMATED TIMEFRAME FOR COMPLETION

Barring any unforeseen circumstances and subject to the approval from our shareholders being obtained, the Proposed Variation is expected to be completed by fourth quarter of 2025.

10. PROPOSALS ANNOUNCED BUT PENDING COMPLETION

Save for the Proposed Variation (which are the subject matter of this Circular), there are no other outstanding proposals which have been announced but not yet completed as at the LPD.

11. EGM

Our EGM will be held at Nexus, Connexion Conference & Event Centre, Spectrum (Level 3A), Bangsar South City, No. 7, Jalan Kerinchi, 59200 Kuala Lumpur, Malaysia on **Friday, 28 November 2025 at 4:00 p.m.** or at any adjournment thereof, or following the conclusion of the 5th Annual General Meeting, whichever is later for the purpose of considering and, if thought fit, passing the resolution as set out in the Notice of EGM enclosed in this Circular, with or without modifications, to give effect to the Proposed Variation.

If you are entitled but unable to attend and vote at our forthcoming EGM, you are requested to complete, sign and lodge the enclosed Proxy Form in accordance with the instructions therein as soon as possible at the office of our Share Registrar at Tricor Investor & Issuing House Services Sdn Bhd, Unit 32-01, Level 32, Tower A, Vertical Business Suite, Avenue 3, Bangsar South, No. 8, Jalan Kerinchi, 59200 Kuala Lumpur or alternatively, at the drop-in box located at Unit G-3, Ground Floor, Vertical Podium, Avenue 3, Bangsar South, No. 8, Jalan Kerinchi, 59200 Kuala Lumpur or by electronic lodgement via the portal at <https://srmy.vistra.com> not later than 48 hours before the time appointed for holding our EGM or at any adjournment thereof, or following the conclusion of the 5th Annual General Meeting, whichever is later. The lodging of the Proxy Form will not preclude you from attending, speaking and voting in person at our EGM should you subsequently wish to do so.

12. FURTHER INFORMATION

You are advised to refer to the **Appendix I** set out in this Circular for further information.

Yours faithfully,
For and on behalf of the Board of
CENGILD MEDICAL BERHAD

DATO' DR. TAN HUCK JOO
Executive Chairman

FURTHER INFORMATION

1. DIRECTORS' RESPONSIBILITY STATEMENT

This Circular has been seen and approved by our Directors and they collectively and individually accept full responsibility for the accuracy of the information contained in this Circular and confirm that, after having made all reasonable enquiries and to the best of their knowledge and belief, there are no other facts, the omission of which would make any statement in this Circular false or misleading.

2. MATERIAL LITIGATION, CLAIMS OR ARBITRATION

As at the LPD, our Group is not engaged in any material litigation, claim or arbitration, either as plaintiff or defendant, and our Board is not aware and does not have any knowledge of any proceedings pending or threatened against our Group, or of any fact likely to give to any proceedings, which might materially and adversely affect the financial position or business of our Group.

3. MATERIAL COMMITMENTS

As at the LPD, our Board is not aware of any material commitments incurred or known to be incurred by our Group that have not been provided for, which upon becoming due or enforceable, may have a material impact on the financial position or financial performance of our Group.

4. CONTINGENT LIABILITIES

As at the LPD, our Board is not aware of any contingent liabilities incurred or known to be incurred by our Group which, upon becoming due or enforceable, may have a material impact on the financial position or financial performance of our Group.

5. DOCUMENTS AVAILABLE FOR INSPECTION

The following documents are available for inspection at our Registered Office during office hours from the date of this Circular up to and including the date of our forthcoming EGM:

- (i) our Company's Constitution; and
- (ii) the audited financial statements of our Group for the FYE 30 June 2024 and FYE 30 June 2025.



CENGILD MEDICAL BERHAD

Registration No.: 202101004143 (1404442-P)
(Incorporated in Malaysia)

NOTICE OF EXTRAORDINARY GENERAL MEETING

NOTICE IS HEREBY GIVEN that an Extraordinary General Meeting (“**EGM**”) of Cengild Medical Berhad (“**Cengild Medical**” or “**Company**”) will be held at Nexus, Connexion Conference & Event Centre, Spectrum (Level 3A), Bangsar South City, No. 7, Jalan Kerinchi, 59200 Kuala Lumpur, Malaysia on **Friday, 28 November 2025 at 4:00 p.m.** or at any adjournment thereof, or following the conclusion of the 5th Annual General Meeting, whichever is later for the purpose of considering and, if thought fit, passing the following ordinary resolution, with or without modifications:

ORDINARY RESOLUTION

PROPOSED VARIATION AND EXTENSION OF TIMEFRAME FOR THE UTILISATION OF PROCEEDS RAISED FROM THE INITIAL PUBLIC OFFERING (“IPO”) OF CENGILD MEDICAL PURSUANT TO RULE 8.24 OF THE ACE MARKET LISTING REQUIREMENTS OF BURSA SECURITIES (“PROPOSED VARIATION”)

“**THAT** approval be and is hereby given to the Company to vary the utilisation of proceeds raised from the public issue under the IPO of the Company and extension of timeframe in the manner as set out in **Section 2** of the Circular to shareholders of the Company dated 30 October 2025.

AND THAT the Board of Directors (“**Board**”) of the Company be and are hereby authorised to take all such steps and do all acts, deeds and things to enter into any arrangements, transactions, agreements and/or undertakings and to execute, sign and deliver on behalf of the Company, all such documents as they may deem necessary, expedient and/or appropriate to implement and give full effect to and to complete the Proposed Variation with full powers to assent to any conditions, modifications, variations and/or amendments as they may in their absolute discretion deem fit, necessary, expedient, appropriate and/or as may be imposed or permitted by any relevant authorities in connection with the Proposed Variation.”

By order of the Board

WONG SIEW YEEN (MAICSA 7018749) (SSM Practicing Certificate No. 202008001471)
TEE THIAM CHAI (MAICSA 7066679) (SSM Practicing Certificate No. 202008002297)

Company Secretaries

Kuala Lumpur
30 October 2025

Notes:

1. *For the purpose of determining who shall be entitled to participate in this EGM, the Company shall be requesting Bursa Malaysia Depository Sdn. Bhd. to make available to the Company, the Record of Depositors as at **21 November 2025**. Only a member whose name appears on this Record of Depositors shall be entitled to participate in this EGM.*
2. *A member who is entitled to participate in this EGM is entitled to appoint a proxy or attorney or in the case of a corporation, to appoint a duly authorised representative to participate in his/her place. A proxy may but need not be a member of the Company.*
3. *A member of the Company who is entitled to attend and vote at this EGM may appoint not more than two (2) proxies to attend, participate, speak and vote instead of the member at this EGM.*
4. *If two (2) proxies are appointed, the entitlement of those proxies to vote on a show of hands shall be in accordance with the listing requirements of the stock exchange.*

5. Where a member of the Company is an authorised nominee as defined in the Securities Industry (Central Depositories) Act 1991 ("**Central Depositories Act**"), it may appoint not more than two (2) proxies in respect of each securities account it holds in ordinary shares of the Company standing to the credit of the said securities account.
6. Where a member of the Company is an exempt authorised nominee which holds ordinary shares in the Company for multiple beneficial owners in one securities account ("**omnibus account**"), there is no limit to the number of proxies which the exempt authorised nominee may appoint in respect of each omnibus account it holds. An exempt authorised nominee refers to an authorised nominee defined under the Central Depositories Act which is exempted from compliance with the provisions of Sections 25A(1) of the Central Depositors Act.
7. Where a member appoints more than one (1) proxy, the proportion of shareholdings to be represented by each proxy must be specified in the instrument appointing the proxies.
8. The appointment of a proxy may be made in a hard copy form or by electronic means in the following manner and must be received by the Company not less than forty-eight (48) hours before the time appointed for holding this EGM or adjourned EGM at which the person named in the appointment proposes to vote:
 - (i) In hard copy form

In the case of an appointment made in hard copy form, the proxy form must be deposited with the Share Registrar of the Company at Tricor Investor & Issuing House Services Sdn. Bhd., Unit 32-01, Level 32, Tower A, Vertical Business Suite, Avenue 3, Bangsar South, No. 8, Jalan Kerinchi, 59200 Kuala Lumpur, Malaysia or alternatively, at the drop-in box located at Unit G-3, Ground Floor, Vertical Podium, Avenue 3, Bangsar South, No. 8 Jalan Kerinchi, 59200 Kuala Lumpur, Malaysia.
 - (ii) By electronic means

The proxy form can be electronically lodged with the Share Registrar of the Company via the portal at <https://srmy.vistra.com>. Please follow the procedures set out in the Administrative Guide.
9. Please ensure ALL the particulars as required in the proxy form are complete, signed and dated accordingly.
10. Last date and time for lodging the proxy form is **Wednesday, 26 November 2025 at 4:00 p.m.**
11. Any authority pursuant to which such an appointment is made by a power of attorney must be deposited with the Share Registrar of the Company at Tricor Investor & Issuing House Services Sdn. Bhd., Unit 32-01, Level 32, Tower A, Vertical Business Suite, Avenue 3, Bangsar South, No. 8, Jalan Kerinchi, 59200 Kuala Lumpur, Malaysia or alternatively, at the drop-in box located at Unit G-3, Ground Floor, Vertical Podium, Avenue 3, Bangsar South, No. 8, Jalan Kerinchi, 59200 Kuala Lumpur, Malaysia not less than forty-eight (48) hours before the time appointed for holding this EGM or adjourned EGM at which the person named in the appointment proposes to vote. A copy of the power of attorney may be accepted provided that it is certified notarially and or in accordance with the applicable legal requirements in the relevant jurisdiction in which it is executed.
12. For a corporate member who has appointed an authorised representative, please deposit the **ORIGINAL** certificate of appointment of authorised representative with the Share Registrar of the Company at Tricor Investor & Issuing House Services Sdn. Bhd., Unit 32-01, Level 32, Tower A, Vertical Business Suite, Avenue 3, Bangsar South, No. 8, Jalan Kerinchi, 59200 Kuala Lumpur, Malaysia or alternatively, at the drop-in box located at Unit G-3, Ground Floor, Vertical Podium, Avenue 3, Bangsar South, No. 8, Jalan Kerinchi, 59200 Kuala Lumpur, Malaysia. The certificate of appointment of authorised representative should be executed in the following manner:
 - (i) If the corporate member has a common seal, the certificate of appointment of authorised representative should be executed under seal in accordance with the constitution of the corporate member.
 - (ii) If the corporate member does not have a common seal, the certificate of appointment of authorised representative should be affixed with the rubber stamp of the corporate member (if any) and executed by:
 - (a) at least two (2) authorised officers, of whom one shall be a director; or
 - (b) any director and/or authorised officers in accordance with the laws of the country under which the corporate member is incorporated.
13. Shareholders are advised to check the Company's website at www.cengild.com and announcements from time to time for any changes to the administration of this EGM that may be necessitated by changes to the directives, safety and precautionary requirements and guidelines prescribed by the Government of Malaysia, the Ministry of Health, the Malaysian National Security Council, Securities Commission Malaysia and/or other relevant authorities.



CENGILD MEDICAL BERHAD
Registration No.: 202101004143 (1404442-P)
(Incorporated in Malaysia)

CDS Account No.

No. of Shares held

PROXY FORM

*I/We _____ Tel: _____
(Full name in block, NRIC / Passport No. / Company Registration No.)

of _____

being member(s) of **CENGILD MEDICAL BERHAD**, hereby appoint:

Full Name (in Block as per NRIC / Passport No.)	NRIC / Passport No.	Proportion of Shareholdings	
		No. of Shares	%
Address			

*and / or

Full Name (in Block as per NRIC / Passport No.)	NRIC/Passport No.	Proportion of Shareholdings	
		No. of Shares	%
Address			

or failing him/her, the Chairman of the Meeting, as *my/our proxy/proxies to vote for *me/us and on *my/our behalf at the Extraordinary General Meeting (“**EGM**”) of the Company which will be held at Nexus, Connexion Conference & Event Centre, Spectrum (Level 3A), Bangsar South City, No. 7, Jalan Kerinchi, 59200 Kuala Lumpur, Malaysia on **Friday, 28 November 2025 at 4:00 p.m.** or any adjournment thereof, or following the conclusion of the 5th Annual General Meeting, whichever is later and to vote as indicated below:

Description of Resolution			For	Against
Ordinary Resolution	-	Proposed Variation		

Please indicate with an “X” in the space provided whether you wish your votes to be cast for or against the resolutions. In the absence of specific direction, your proxy will vote or abstain as he/she thinks fit.

Signed this _____ day of _____ 2025

Signature / Common Seal

* Delete whichever not applicable

Notes:

1. For the purpose of determining who shall be entitled to participate in this EGM, the Company shall be requesting Bursa Malaysia Depository Sdn. Bhd. to make available to the Company, the Record of Depositors as at **21 November 2025**. Only a member whose name appears on this Record of Depositors shall be entitled to participate in this EGM.
2. A member who is entitled to participate in this EGM is entitled to appoint a proxy or attorney or in the case of a corporation, to appoint a duly authorised representative to participate in his/her place. A proxy may but need not be a member of the Company.
3. A member of the Company who is entitled to attend and vote at this EGM of the Company may appoint not more than two (2) proxies to attend, participate, speak and vote instead of the member at this EGM.
4. If two (2) proxies are appointed, the entitlement of those proxies to vote on a show of hands shall be in accordance with the listing requirements of the stock exchange.
5. Where a member of the Company is an authorised nominee as defined in the Securities Industry (Central Depositories) Act 1991 ("**Central Depositories Act**"), it may appoint not more than two (2) proxies in respect of each securities account it holds in ordinary shares of the Company standing to the credit of the said securities account.
6. Where a member of the Company is an exempt authorised nominee which holds ordinary shares in the Company for multiple beneficial owners in one securities account ("**omnibus account**"), there is no limit to the number of proxies which the exempt authorised nominee may appoint in respect of each omnibus account it holds. An exempt authorised nominee refers to an authorised nominee defined under the Central Depositories Act which is exempted from compliance with the provisions of Sections 25A(1) of the Central Depositors Act.
7. Where a member appoints more than one (1) proxy, the proportion of shareholdings to be represented by each proxy must be specified in the instrument appointing the proxies.
8. The appointment of a proxy may be made in a hard copy form or by electronic means in the following manner and must be received by the Company not less than forty-eight (48) hours before the time appointed for holding this EGM or adjourned EGM at which the person named in the appointment proposes to vote.
 - (i) In hard copy form

In the case of an appointment made in hard copy form, the proxy form must be deposited with the Share Registrar of the Company at Tricor Investor & Issuing House Services Sdn. Bhd., Unit 32-01, Level 32, Tower A, Vertical Business Suite, Avenue 3, Bangsar South, No. 8, Jalan Kerinchi, 59200 Kuala Lumpur, Malaysia or alternatively, at the drop-in box located at Unit G-3, Ground Floor, Vertical Podium, Avenue 3, Bangsar South, No. 8, Jalan Kerinchi, 59200 Kuala Lumpur, Malaysia.
 - (ii) By electronic means

The proxy form can be electronically lodged with the Share Registrar of the Company via the portal at <https://srmy.vistra.com>. Please follow the procedures set out in the Administrative Guide.
9. Please ensure ALL the particulars as required in the proxy form are complete, signed and dated accordingly.
10. Last date and time for lodging the proxy form is **Wednesday, 26 November 2025 at 4:00 p.m.**
11. Any authority pursuant to which such an appointment is made by a power of attorney must be deposited with the Share Registrar of the Company at Tricor Investor & Issuing House Services Sdn. Bhd., Unit 32-01, Level 32, Tower A, Vertical Business Suite, Avenue 3, Bangsar South, No. 8, Jalan Kerinchi, 59200 Kuala Lumpur, Malaysia or alternatively, at the drop-in box located at Unit G-3, Ground Floor, Vertical Podium, Avenue 3, Bangsar South, No. 8, Jalan Kerinchi, 59200 Kuala Lumpur, Malaysia not less than forty-eight (48) hours before the time appointed for holding this EGM or adjourned EGM at which the person named in the appointment proposes to vote. A copy of the power of attorney may be accepted provided that it is certified notarially and or in accordance with the applicable legal requirements in the relevant jurisdiction in which it is executed.
12. For a corporate member who has appointed an authorised representative, please deposit the **ORIGINAL** certificate of appointment of authorised representative with the Share Registrar of the Company at Tricor Investor & Issuing House Services Sdn. Bhd., Unit 32-01, Level 32, Tower A, Vertical Business Suite, Avenue 3, Bangsar South, No. 8, Jalan Kerinchi, 59200 Kuala Lumpur, Malaysia or alternatively, at the drop-in box located at Unit G-3, Ground Floor, Vertical Podium, Avenue 3, Bangsar South, No. 8, Jalan Kerinchi, 59200 Kuala Lumpur, Malaysia. The certificate of appointment of authorised representative should be executed in the following manner:
 - (i) If the corporate member has a common seal, the certificate of appointment of authorised representative should be executed under seal in accordance with the constitution of the corporate member.

- (ii) *If the corporate member does not have a common seal, the certificate of appointment of authorised representative should be affixed with the rubber stamp of the corporate member (if any) and executed by:*
 - (a) *at least two (2) authorised officers, of whom one shall be a director; or*
 - (b) *any director and/or authorised officers in accordance with the laws of the country under which the corporate member is incorporated.*
- 13. *Shareholders are advised to check the Company's website at www.cengild.com and announcements from time to time for any changes to the administration of this EGM that may be necessitated by changes to the directives, safety and precautionary requirements and guidelines prescribed by the Government of Malaysia, the Ministry of Health, the Malaysian National Security Council, Securities Commission Malaysia and/or other relevant authorities.*

Fold this flap for sealing

Then fold here

AFFIX
STAMP

CENGILD MEDICAL BERHAD
Registration No. 202101004143 (1404442-P)
c/o Tricor Investor & Issuing House Services Sdn Bhd
Unit 32-01, Level 32, Tower A
Vertical Business Suite, Avenue 3
Bangsar South, No. 8, Jalan Kerinchi
59200 Kuala Lumpur

1st fold here

[The rest of this page is intentionally left blank]

[The rest of this page is intentionally left blank]